JPRN-jRCT2080221706未知1 期
Phase I trial of YHI-1003 Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients were previously diagnosed with multiple myeloma
- •(2)Patients must have relapsed after their last dose of bortezomib-based therapy
- •(3)Patients must have received 1 to 4-myeloma therapies
- •(4)ECOG performance status (PS) :0-2
排除标准
- •(1)Patients with uncontrolled intercurrent illness
- •(2)Female patients who are pregnant or lactating
- •(3)Patients with non-secretory multiple myeloma
研究者
相似试验
未知
2 期
Phase II trial of YHI-1003JPRN-jRCT2080222238Yakult Honsha Co., Ltd.96
未知
1 期
A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapyJPRN-jRCT2080222078Yakult Honsha Co., Ltd.164
未知
1 期
Phase I/II trial of YHI-1003 plus CapecitabineJPRN-jRCT2080221670Yakult Honsha Co.,Ltd.50
未知
1 期
Phase I trial of YHI-1003relapsed or refractory neuroblastomaJPRN-jRCT2080222084Yakult Honsha Co., Ltd.18
未知
1 期
Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapyPatients with non-small cell lung cancer who have received platinum-based chemotherapyJPRN-jRCT2080222077Yakult Honsha Co., Ltd.118